SCHEMBL19366371

SCHEMBL19366371

C/N=C/c1ccc(C(=O)Nc2cccc(-n3cnc4ccccc43)c2)cc1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 5/20 0.47
RAB9A P51151 2/20 0.47
NPC1 O15118 1/20 0.47
ALDH1A1 P00352 3/20 0.45
KDM4E B2RXH2 1/20 0.45
MAPT P10636 1/20 0.45
BLM P54132 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CTDSP1 Q9GZU7 1/20 0.45
PRNP P04156 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
POLB P06746 1/20 0.43
AURKA O14965 1/20 0.43
KDR P35968 1/20 0.43
AURKB Q96GD4 1/20 0.43
GAA P10253 2/20 0.43
TP53 P04637 1/20 0.42
ORAI1 Q96D31 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19067864 1.00 FGFR1 (0.47) FGFR1RAB9ANPC1ALDH1A1KDM4E
SCHEMBL16158512 0.88 POLB (0.57) FGFR1RAB9ANPC1ALDH1A1KDM4E
SCHEMBL17498832 0.86 AURKB (0.54) FGFR1ALDH1A1PRNPL3MBTL1MEN1
SCHEMBL17498780 0.84 FGFR1 (0.51) FGFR1RAB9ANPC1ALDH1A1MEN1
SCHEMBL16158513 0.84 FGFR1 (0.56) FGFR1RAB9ANPC1ALDH1A1MAPT
SCHEMBL16158534 0.84 L3MBTL1 (0.60) FGFR1ALDH1A1KDM4EMAPTSMN1; SMN2
SCHEMBL16158511 0.83 FGFR1 (0.48) FGFR1ALDH1A1PRNPL3MBTL1MEN1
SCHEMBL16147363 0.81 FGFR1 (0.62) FGFR1RAB9ANPC1ALDH1A1MAPT
SCHEMBL17531412 0.81 TP53 (0.56) FGFR1RAB9ANPC1ALDH1A1KDM4E
SCHEMBL16158510 0.80 FGFR1 (0.70) FGFR1RAB9ANPC1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10617685-B2 Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity UNIVERSITY OF MARYLAND, BALTIMORE (US) 2020-04-14 US disclosed
US-20170266181-A1 NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY UNIVERSITY OF MARYLAND, BALTIMORE (US) 2017-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10617685-B2 Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity AR, NR5A1, BRCA1 FGFR1 1290/4885RAB9A 4339/4885NPC1 1426/4885
US-20170266181-A1 NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY AR, NR5A1, BRCA1 FGFR1 1290/4885RAB9A 4339/4885NPC1 1426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.